Procarbazine

• 

  Subject Areas on Research

  • A malignant lymphoma with histological features and immunophenotypic profile intermediate between EBV-positive diffuse large B-cell lymphoma and EBV-positive classical Hodgkin lymphoma in a 67-year-old female: a "gray zone" lymphoma associated with Epstein-Barr virus in the elderly. 
  • A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse. 
  • A phase II window trial of procarbazine and topotecan in children with high-grade glioma: a report from the children's oncology group. 
  • A pilot study of dose-intensified procarbazine, CCNU, vincristine for poor prognosis brain tumors utilizing fibronectin-assisted, retroviral-mediated modification of CD34+ peripheral blood cells with O6-methylguanine DNA methyltransferase. 
  • Activity of temozolomide in the treatment of central nervous system tumor xenografts. 
  • Acute leukemia following treatment of malignant glioma. 
  • Allogeneic marrow transplantation in the treatment of MOPP-resistant Hodgkin's disease. 
  • CALGB 50604: risk-adapted treatment of nonbulky early-stage Hodgkin lymphoma based on interim PET. 
  • CEPP(B): an effective and well-tolerated regimen in poor-risk, aggressive non-Hodgkin's lymphoma. 
  • Cilengitide with metronomic temozolomide, procarbazine, and standard radiotherapy in patients with glioblastoma and unmethylated MGMT gene promoter in ExCentric, an open-label phase II trial. 
  • Combined modality therapy for advanced, diffuse lymphocytic and histiocytic lymphomas. 
  • Combined modality therapy of advanced non-Hodgkin's lymphoma: an analysis of remission duration and survival in 95 patients. 
  • Criteria for termination of phase II chemotherapy for patients with progressive or recurrent brain tumor. 
  • Hodgkin's disease presenting as myelofibrosis. 
  • Immediate and delayed neurotoxicity after mechlorethamine preparation for bone marrow transplantation. 
  • In vitro sensitivity testing of minimally passaged and uncultured gliomas with TRAIL and/or chemotherapy drugs. 
  • Intracerebral growth of a human glioma tumor line in athymic mice and treatment with procarbazine, 1,3-bis(2-chloroethyl)-1-nitrosourea, aziridinylbenzoquinone, and cis-platinum. 
  • Long-term follow-up of survival in Hodgkin's lymphoma. 
  • O6-alkylguanine-DNA alkyltransferase and sensitivity to procarbazine in human brain-tumor xenografts. 
  • POG 8625: a randomized trial comparing chemotherapy with chemoradiotherapy for children and adolescents with Stages I, IIA, IIIA1 Hodgkin Disease: a report from the Children's Oncology Group. 
  • Positive therapeutic interaction between thiopurines and alkylating drugs in human glioma xenografts. 
  • Pregnancy after chemotherapy in male and female survivors of childhood cancer treated between 1970 and 1999: a report from the Childhood Cancer Survivor Study cohort. 
  • Radiation as salvage therapy for patients with Hodgkin's disease relapsing after MOPP (mechlorethamine, vincristine, prednisone, and procarbazine) chemotherapy. 
  • Radiation dose selection in Hodgkin's disease patients with large mediastinal adenopathy treated with combined modality therapy. 
  • Retroperitoneal fibrosis following treatment for Hodgkin's disease. 
  • Secondary gastrointestinal cancer in childhood cancer survivors: a cohort study. 
  • Stage IA to IIB mediastinal Hodgkin's disease: three-dimensional volumetric assessment of response to treatment. 
  • Summaries for patients. Increased risk for gastrointestinal cancer in childhood cancer survivors. 
  • Treatment of five subcutaneous human glioma tumor lines in athymic mice with carmustine, procarbazine, and mithramycin.